Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Stomach 'EKG' could spot hidden gut problems

NCT ID NCT05812339

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a new device called Gastric Alimetry that records the stomach's electrical activity through electrodes placed on the belly. Researchers want to see if it can reliably detect abnormal stomach rhythms in people with conditions like gastroparesis and functional dyspepsia. 200 adults (both healthy and with stomach symptoms) will wear the device for 4 hours after a meal. The goal is to validate the device as a diagnostic tool, not to treat any condition.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Gastric Alimetry System (a device with electrodes placed on the abdomen to record stomach electrical activity)
What this could lead to
If successful, this device could become a new, non-invasive tool to help doctors diagnose stomach motility problems more accurately.
What could go wrong
This is an early observational study to validate the device, not a treatment trial. It may not lead to a widely available diagnostic test, and skin irritation from the electrodes is possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2022

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults living in the Calgary Alberta region.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Healthy Population: * Adults aged 18 years and over * Able to understand the risks/benefits of the study * Able to give written informed consent * No active gastrointestinal symptoms or pathology * Resides in the Calgary, Alberta area Patient Population: * Adults aged 18 years and over * BMI \> 35 * Able to understand the risks/benefits of the study * Able to give written informed consent * Patients meeting Rome IV Criteria for functional dyspepsia, or a nausea and vomiting disorder * Patients with gastroparesis defined on a standardized gastric scintigraphy study * Resides in the Calgary, Alberta area Exclusion Criteria: Healthy Population: * Under 18 years of age * BMI \> 35 * Taking medications known to affect GI motility or the mid-gut axis (eg antidepressants, anti-anxiety medication, prokinetics, opiates) * Metabolic, neurogenic, or endocrine disorders known to cause gastrointestinal dysmotility (eg. Multiple Sclerosis, Parkinson's disease, hypothyroidism) * Known current GI infection (includes H. pylori when being actively treated) * Known current inflammatory bowel disease * Known current GI malignancy * Known GI functional or motility disorders * Previous gastroduodenal surgery * GI functional or motility disorders * Pregnant women * Open abdominal wounds or abdominal skin not intact (eg rash, abrasions, weeping tissue) * Fragile skin evidence by high susceptibility to skin tears or skin that bruises and breaks easily * Allergy to adhesives * History of allergy or intolerance to ingredients in the meal (nutrient drink, Ensure or similar and Clif bar or similar) * No vulnerable groups such as; prisoners, individuals with known cognitive impairment, or institutionalised individuals be involved * Regular cannabis use * Diagnosed with, or suspected to have life-threatening conditions that could result in immediate danger Patient Population: * Under 18 years of age * BMI \> 35 * Metabolic, neurogenic, or endocrine disorders known to cause gastrointestinal dysmotility (eg. Multiple Sclerosis, Parkinson's disease, hypothyroidism) * Known current GI infection (includes H. pylori when being actively treated) * Known current inflammatory bowel disease * Known current GI malignancy * Previous gastroduodenal surgery * Open abdominal wounds or abdominal skin not intact (eg rash, abrasions, weeping tissue) * Fragile skin evidence by high susceptibility to skin tears or skin that bruises and breaks easily * Allergy to adhesives * Pregnant women * History of allergy or intolerance to ingredients in the meal (nutrient drink, Ensure or similar and Clif bar or similar) * No vulnerable groups such as; prisoners, individuals with known cognitive impairment, or institutionalised individuals be involved * Regular cannabis use except in the case of CHS * Diagnosed with, or suspected to have life-threatening conditions that could result in immediate danger * Inability to remain in a relaxed reclined position for the test duration

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cannabinoid hyperemesis syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Calgary

    Calgary, Alberta, T2N 4Z6, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.